RxDoctor Payments Data

Feras Elhajj, MD

Family Medicine · Magnolia, TXNPI 1811997596

Payments from drug & device makers

$82,251in general payments, 2019–2025

Across 768 payments — averaging $107.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$28K
  • Lilly USA, LLC$22K
  • Janssen Research & Development, LLC$18K
  • Eli Lilly$5K
  • Novo Nordisk$2K
  • AbbVie$1K
  • plus $7K from 48 others

What the payments were for

  • Consulting fees$18,25049%
  • Speaking & faculty fees$2,7507%
  • Travel & lodging$3,60410%
  • Food & beverage$12,41934%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,251 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$148,049
Medicare patients
234
Services billed
2,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide121$123,966
JardianceEmpagliflozin61$61,334
MounjaroTirzepatide42$44,618
TrulicityDulaglutide29$40,724
ArexvyRsvpref3 Antigen/As01e/Pf135$39,724
EliquisApixaban48$33,951
Xigduo XrDapaglifloz Propaned/Metformin26$25,925
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$25,327
XareltoRivaroxaban19$19,679
JanumetSitagliptin Phos/Metformin Hcl14$18,535
Repatha SureclickEvolocumab28$16,388
JanuviaSitagliptin Phosphate17$15,984
FarxigaDapagliflozin Propanediol13$10,882
Ergotamine-CaffeineErgotamine Tartrate/Caffeine17$9,228
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$8,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,873$123,966121 claims
Lilly USA, LLCMounjaro, Trulicity$21,616$85,34371 claims
GSKArexvy, Trelegy Ellipta, Shingrix$28,093$70,689202 claims
Boehringer IngelheimJardiance$385$61,33461 claims
PfizerEliquis, Abrysvo$408$40,08568 claims
MerckJanumet, Januvia$249$34,51931 claims
Johnson & JohnsonXarelto$154$19,67919 claims
AstraZenecaFarxiga$1,001$10,88213 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$120$6,70711 claims
Astellas Pharma US IncMyrbetriq$350$6,65415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Magnolia

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →